Tweets
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
No Risk of RA w/ coffee consumption -- Swedish EIRA study, included 2184 early RA pts. High Coffee (>6 cups/day) was assoc w/ increased RA risk (OR 1.50;1.20–1.88) that was lost after adjusting for smoking (OR 1.14;0.89–1.45). https://t.co/3SIeHD4fII https://t.co/NqkjmuzSaV
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
https://t.co/7rUuB6RRow https://t.co/MqBjOj1myW
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
Metanalysis of 13 trials of corticosteroids (CS) in hand #OA shows no significant effect of intra-articular CS for CMC1 OA (pain or function); but medium effect of oral CS on pain & stiffness & functional improvement at 4-6 weeks. https://t.co/u30bPuQOOr https://t.co/4Z1ZpiOcvX
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/BjvUm0wPNk https://t.co/IVisAgD1wZ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4
Figures https://t.co/yIECjLiEwl
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders.
https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
Every moderately to severely immunocompromised person should know about Evusheld, a preventive Rx. It's uncommonly prescribed by doctors and there's a general lack of awareness. Still works vs BA.5
An excellent patient page @JAMA_current https://t.co/Exn82D8712 @AnuMalaniMD https://t.co/Rpdhcgg33h
Eric Topol @EricTopol ( View Tweet )
3 years 11 months ago
Risk of hospitalized infection (SIE) goes up with #RA disease activity. Study of 3,254 RA Pts with 529 SIE - SIE rates lowest with remission (3.8/100PY), vs low dz activity (6.6/100PY; OR 1.60) vs moderate activity (8.8/100PY; OR 183) https://t.co/EWbX7N7fiG https://t.co/Y8bRn2XATF
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
New download available on the diagnosis & treatment of Still's Disease.
Register on RheumNow and download for immediate use.
https://t.co/YvgsEtVHVc https://t.co/N9K0cjfakC
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago
Tonight! Sign up for Tuesday Night Rheumatology at 7pm!
https://t.co/bnEXGUeeyx https://t.co/A4MaXWfhRO
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 11 months ago


